Drug Profile
SON 1210
Alternative Names: IL15-FHAB-IL12; SON-1210Latest Information Update: 17 Jan 2024
Price :
$50
*
At a glance
- Originator Sonnet Biotherapeutics
- Developer Sonnet BioTherapeutics Holdings, Inc
- Class Antineoplastics; Interleukins; Recombinant fusion proteins
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 17 Jan 2024 Preclinical development is ongoing in Colorectal-cancer in USA (Parenteral) (Sonnet Biotherapeutics pipeline, January 2024)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
- 08 Feb 2022 Sonnet BioTherapeutics plans initiation of a non-GLP pre-clinical toxicity study in non-human primates for first half of 2022